Broadridge Financial Solutions heads into mid-June with a stock that has slipped 4% on the week while options positioning has shifted notably more optimistic — a divergence worth watching.
The clearest signal this week is in options. The put/call ratio has dropped to 1.25, almost 1.5 standard deviations below its 20-day average of 1.67. That is the least defensive options positioning Broadridge has seen in weeks. The PCR spent much of May running close to 2.0; that hedging demand has unwound sharply through June, even as the stock has sold off. Call buyers have been gaining relative to put holders — a posture that runs against the grain of the week's price action.
Short interest tells a different story, though not an alarming one. Bears have modestly rebuilt positions over the past month, with SI climbing roughly 10% to reach 2.9% of free float — a level that remains well within low territory. Borrow is essentially free at 0.46%, up about 13% on the week but still negligible in absolute terms. Availability is vast: the lending pool is barely touched, with only 0.58% of available shares lent out. There is no squeeze pressure here, and no meaningful cost hurdle for new shorts. The short score of 32.5 has ticked up slightly from mid-week lows but remains subdued — positioning looks relaxed rather than hostile.
The Street remains constructive but has been trimming its ambitions. Following the late-April and early-May earnings reaction — where the stock fell roughly 3.4% on the day and nearly 5% over the subsequent week — analysts across DA Davidson, RBC Capital, Needham, and UBS all maintained their ratings while cutting targets, some sharply. UBS lowered its target to $165 from $250; the consensus mean now sits around $206, implying roughly 43% upside from current levels at $143.88. That gap deserves a sanity check: the target compression looks earnings-driven rather than a data error, but it reflects real uncertainty about growth cadence. The bull case centres on recurring revenue growing 9% and closed sales up 24% year-over-year. The bear case focuses on event-driven revenue tumbling 27% and the prospect that flat adjusted operating margins offer limited earnings leverage if macro conditions weaken. Valuation multiples have compressed — the P/E has pulled back over 30 days and the price-to-book has eased — making the stock meaningfully cheaper than it was in late 2025, when these same analysts were carrying targets above $250.
One insider data point stands out. CEO Timothy Gokey bought 5,300 shares in early March at roughly $194 each, a purchase totalling just over $1 million. The stock has since fallen another 26% from that entry. That is not a bearish signal on its own, but it does frame the current $143 level as sitting well below where the company's own chief executive put real money to work. The Chief Legal Officer has since sold smaller amounts in routine transactions, but net insider activity over the past 90 days is positive at roughly $1.5 million in net purchases — driven almost entirely by that CEO buy.
Among close peers, the week's weakness was broad. ADP fell about 4% and Genpact dropped a similar amount. Paychex was flat. Paylocity fared worst, off nearly 8%. The group-wide softness suggests sector-level pressure rather than anything specific to Broadridge. Next up is the August 6 earnings report — the question heading into that print is whether recurring revenue momentum can offset continued event-driven softness, and whether management's 9-12% EPS growth guidance holds up under scrutiny.
See the live data behind this article on ORTEX.
Open BR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
